In preclinical models, Alpelisib exhibited robust inhibitory efficacy against cancer cell lines characterized by PIK3CA mutations, alongside its capacity to diminish tumor progression within xenograft models harboring PIK3CA mutations [121]. This evidence concerns the gene PIK3CA and neoplasm.